Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, PT Indofarma Tbk's Enterprise Value is Rp1,118,378 Mil.
PT Indofarma Tbk's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was Rp-190,884 Mil. Therefore, PT Indofarma Tbk's EV-to-OCF for today is -5.86.
The historical rank and industry rank for PT Indofarma Tbk's EV-to-OCF or its related term are showing as below:
ISX:INAF'
s EV-to-OCF Range Over the Past 10 Years
Min: -490.61 Med: -5.85 Max: 595.24
Current: -5.86
During the past 13 years, the highest EV-to-OCF of PT Indofarma Tbk was 595.24. The lowest was -490.61. And the median was -5.85.
ISX:INAF's EV-to-OCF is not ranked
in the Drug Manufacturers industry.
Industry Median: 10.54
vs ISX:INAF: -5.86
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PT Indofarma Tbk's PE Ratio (TTM) for today is calculated as:
PT Indofarma Tbk's share price for today is Rp126.00.
PT Indofarma Tbk's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp-21.811.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
PT Indofarma Tbk EV-to-OCF Related Terms
PT Indofarma Tbk EV-to-OCF Historical Data
* Premium members only.
The historical data trend for PT Indofarma Tbk's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PT Indofarma Tbk's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Indofarma Tbk EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Indofarma Tbk's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where PT Indofarma Tbk's EV-to-OCF falls into.
PT Indofarma Tbk's current Enterprise Value is Rp1,118,378 Mil.
PT Indofarma Tbk's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp-190,884 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Indofarma Tbk (ISX:INAF) has a EV-to-OCF of -5.86 as of Aug. 27, 2026.
Is PT Indofarma Tbk's EV-to-OCF too high?
PT Indofarma Tbk's current EV-to-OCF is -5.86. Overall, PT Indofarma Tbk has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does PT Indofarma Tbk's EV-to-OCF compare to ZTS and VTRS?
PT Indofarma Tbk's EV-to-OCF of -5.86 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-OCF is 10.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.54, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Indofarma Tbk's current EV-to-OCF is -5.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Indofarma Tbk stock overvalued right now?
PT Indofarma Tbk (ISX:INAF) has a current EV-to-OCF of -5.86. The stock's GF Value™ is Rp176.99, compared to a current price of Rp126.00 — trading 28.8% below its estimated fair value. The current EV-to-OCF is -5.86. PT Indofarma Tbk's overall GF Score™ is 8/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For PT Indofarma Tbk (ISX:INAF), the current EV-to-OCF is -5.86 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Indofarma Tbk (ISX:INAF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Indofarma Tbk stock appears to be undervalued.
The current stock price of Rp126.00 is trading 28.8% below its estimated GF Value™ of Rp176.99.
Key valuation signals for ISX:INAF:
EV-to-OCF: -5.86
GF Value™: Rp176.99 vs. price of Rp126.00 (28.8% below fair value)
No single metric tells the full story. See the ISX:INAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others. The Medicine business segment includes drug production, marketing distribution, and sales. The Medical Device Segment includes medical devices and other products. Company generates majority revenue from the Medicine segment. The Company classifies its distribution segments based on geographic regions into six areas, namely Java, Sumatra, Kalimantan, Sulawesi, Bali dan West Nusa Tenggara (NTB),as well as the Eastern Indonesia region.
8GF Score
Get the complete analysis for ISX:INAF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:INAF has been successfully added to your 
